 REDWOOD CITY, Calif., Sept. 07, 2021 GLOBE NEWSWIRE -- Guardant Health, Inc. Nasdaq: GH along with leading academic institutions and pharmaceutical companies will present data demonstrating the advantages of using the Guardant360 liquid biopsy test for clinical decision-making in advanced lung cancer at the IASLC 2021 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, September 8-14, 2021. 